Showing posts with label abstract. Show all posts
Showing posts with label abstract. Show all posts

Saturday, May 23, 2026

#Andes virus on a cruise #ship: person-to-person #transmission and an empty #pipeline

 


{Extract}

The outbreak of Andes virus aboard the expedition cruise ship MV Hondius with 10 cases, three deaths, and more than 440 contacts including passengers of 23 nationalities, is a stark reminder that neglected zoonotic viruses can rapidly become international public health emergencies.

A WHO-led emergency scientific consultation on May 15, 2026, convened experts to assess the situation and coordinate research priorities.1 The outbreak in the ship might have potentially involved up to three generations of person-to-person transmission from a single index case, with two epidemic peaks during 18 days and one asymptomatic PCR-positive case. The meeting highlighted three urgent realities: the Andes virus can sustain person-to-person transmission, the medical countermeasure pipeline remains immature, and existing scientific networks require urgent support.

(...)

Source: 


Link: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00283-5/fulltext?rss=yes

____

#Coronavirus Disease Research #References (AMEDEO, May 23 '26)

 


    Am J Respir Crit Care Med

  1. KRAMER L, Calfee CS, Mcauley DF, O'Kane C, et al
    Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.
    Am J Respir Crit Care Med. 2026 Apr 28:aamag213. doi: 10.1093.
    PubMed         Abstract available


    Ann Intern Med

  2. MILLER M, Fischer S, Azrael D
    Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey.
    Ann Intern Med. 2026;179:637-644.
    PubMed         Abstract available


    Antiviral Res

  3. LOISON S, Chabert M, Gensous C, Constant S, et al
    Cell-Type Specific Effects of SARS-CoV-2 P252L Mutation on Nirmatrelvir Sensitivity.
    Antiviral Res. 2026 May 19:106445. doi: 10.1016/j.antiviral.2026.106445.
    PubMed         Abstract available

  4. PAGLIARI M, Lutken C, Vianello L, Mazzacan E, et al
    LTX-109 as a broad-spectrum antiviral: in vitro and in vivo efficacy against SARS-CoV-2 and Influenza Viruses.
    Antiviral Res. 2026 May 19:106444. doi: 10.1016/j.antiviral.2026.106444.
    PubMed         Abstract available


    Int J Infect Dis

  5. ERIGUCHI Y, Shimono N
    Declining antibiotic consumption and changing sexually transmitted infection dynamics in Japan: a national ecological time-series analysis, 2013-2024.
    Int J Infect Dis. 2026 May 16:108804. doi: 10.1016/j.ijid.2026.108804.
    PubMed         Abstract available

  6. MA Q, Yao L, Shang H, Han X, et al
    Reply to comment on SARS-CoV-2 variant-specific humoral immunity and long-term immune recovery in people living with HIV in the ancestral vaccine era.
    Int J Infect Dis. 2026 May 17:108812. doi: 10.1016/j.ijid.2026.108812.
    PubMed        

  7. ABERA EG, Kisch R, Ali S, Tsegaye W, et al
    Dynamics and variant-specific patterns of SARS-CoV-2 reinfection in Ethiopia: a prospective longitudinal cohort study.
    Int J Infect Dis. 2026 May 18:108814. doi: 10.1016/j.ijid.2026.108814.
    PubMed         Abstract available


    J Infect

  8. MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
    A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
    J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
    PubMed         Abstract available

  9. GUINOVART LJ, Westrhenen SEMH, Schuurman R, Bruijning-Verhagen PCJL, et al
    Symptomatology of SARS-CoV-2 versus seasonal coronavirus infection in healthy young children.
    J Infect. 2026 May 20:106762. doi: 10.1016/j.jinf.2026.106762.
    PubMed         Abstract available


    J Med Virol

  10. BU GL, Chen LN, Wu PH, Zeng MS, et al
    Preventing Both EBV Infection and EBV-Associated Diseases: Advances in Vaccine Research.
    J Med Virol. 2026;98:e70961.
    PubMed         Abstract available

  11. FUKUDA Y, Fujii Y, Togashi A, Nawa T, et al
    Recent Increase in Rotavirus Gastroenteritis After Five Years of Low Activity in Hokkaido Prefecture, Japan, Associated With Equine-Like G3P[8] and G8P[8] Strains, 2025.
    J Med Virol. 2026;98:e70967.
    PubMed         Abstract available

  12. SANSONE NMS, Costa PT, Mello LS, Marques LFA, et al
    Vaccination Coverage Against Coronavirus Disease 2019 (COVID-19) in Brazil's Indigenous Population.
    J Med Virol. 2026;98:e70965.
    PubMed         Abstract available

  13. HORI M, Hayama-Terada M, Kitamura A, Hosozawa M, et al
    Prevalence and Risk Factors for Persistent Post-COVID-19 Condition at 3, 6, 12, and 18 Months After Initial Infection Among Adults Living in a Community of Japan: Yao COVID-19 Study.
    J Med Virol. 2026;98:e70973.
    PubMed         Abstract available

  14. YENOKYAN K, Wentz E, Ni Z, Kammerling T, et al
    Association of Comorbid and Incident Depression and Other Mental Health Conditions With Long-COVID: Results From the Johns Hopkins COVID Long Study.
    J Med Virol. 2026;98:e70970.
    PubMed         Abstract available


    J Virol

  15. YAN P, Kyaw ZO, Wang X, Li N, et al
    Febrifugine dihydrochloride restricts porcine epidemic diarrhea virus replication by modulating the IGF1R-driven PI3K/AKT-apoptosis axis.
    J Virol. 2026;100:e0011726.
    PubMed         Abstract available

  16. HUANG M, Liukang C, Yang H, Sun L, et al
    Infectious bronchitis virus accessory protein 3a induces renal inflammatory injury by activating the NLRP3 inflammasome via ER calcium mobilization and mitochondrial ROS production.
    J Virol. 2026;100:e0212525.
    PubMed         Abstract available

  17. SCHIFFER JT, Reeves DB, Mayer B, Rodriguez LR, et al
    Clinical trial simulation of antiviral drugs.
    J Virol. 2026;100:e0181424.
    PubMed         Abstract available

  18. SIVARAJAN R, Kirchgatterer PC, Lawrenz J, Tanner-Matiz E, et al
    Tonic and early interferons defend against respiratory viruses in primary human lung organoid-derived air-liquid interface cultures.
    J Virol. 2026 May 20:e0210425. doi: 10.1128/jvi.02104.
    PubMed         Abstract available


    Lancet

  19. ISLAM MS, Chughtai AA, Wood JG, Sawleshwarkar S, et al
    Hantavirus outbreak on a cruise ship in the South Atlantic.
    Lancet. 2026 May 15:S0140-6736(26)00934-7. doi: 10.1016/S0140-6736(26)00934.
    PubMed        


    Nature

  20. AYGUN E, Belyaeva A, Comanici G, Coram M, et al
    An AI system to help scientists write expert-level empirical software.
    Nature. 2026 May 19. doi: 10.1038/s41586-026-10658.
    PubMed         Abstract available

  21. KOZLOV M
    Exclusive: NIH ousts infectious-disease leaders as COVID scientists face US charges.
    Nature. 2026 May 15. doi: 10.1038/d41586-026-01558.
    PubMed        


    Science

  22. COHEN J
    Virologist accused of starting COVID-19 fights funding ban.
    Science. 2026;392:795-796.
    PubMed         Abstract available


    Travel Med Infect Dis

  23. LI D, Tian F, Niu Y, Li H, et al
    Surveillance of Airborne Microorganisms and Associated Influencing Factors at an International Airport in China, 2019-2020.
    Travel Med Infect Dis. 2026 May 19:102992. doi: 10.1016/j.tmaid.2026.102992.
    PubMed         Abstract available

  24. POLONI A, Rizzo A, Giacomelli A, Colaneri M, et al
    D-dimer as a marker of severe disease in imported malaria: a retrospective observational study.
    Travel Med Infect Dis. 2026;72:102994.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 23 '26)

 


    Ann Intern Med

  1. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
    Infectious Diseases: What You May Have Missed in 2025.
    Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
    PubMed         Abstract available

  2. REIS G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, et al
    The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.
    Ann Intern Med. 2026 Mar 31. doi: 10.7326/ANNALS-25-03959.
    PubMed         Abstract available

  3. MILLER M, Fischer S, Azrael D
    Firearm Acquisition and New Exposure to Household Firearms After the Initial Pandemic Purchasing Surge: Results From the 2024 National Firearms Survey.
    Ann Intern Med. 2026;179:637-644.
    PubMed         Abstract available

  4. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
    Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
    Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05485.
    PubMed         Abstract available

  5. MOSER ITK, Dobrescu AI, Sommer I, Goeschl S, et al
    Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
    Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05536.
    PubMed         Abstract available

  6. QASEEM A, Obley AJ, Harrod CS, Wilt TJ, et al
    COVID-19 Vaccines for 2025-2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians.
    Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05026.
    PubMed         Abstract available

  7. DOBRESCU A, Pinte L, Sharifan A, Gadinger A, et al
    Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians.
    Ann Intern Med. 2026 Feb 24. doi: 10.7326/ANNALS-25-05044.
    PubMed         Abstract available


    Antiviral Res

  8. PAGLIARI M, Lutken C, Vianello L, Mazzacan E, et al
    LTX-109 as a broad-spectrum antiviral: in vitro and in vivo efficacy against SARS-CoV-2 and Influenza Viruses.
    Antiviral Res. 2026 May 19:106444. doi: 10.1016/j.antiviral.2026.106444.
    PubMed         Abstract available

  9. WANG W, Yang F, Liu K, Cai M, et al
    A mouse model of human-derived H10N3 influenza enables preclinical evaluation of antiviral efficacy.
    Antiviral Res. 2026 May 18:106436. doi: 10.1016/j.antiviral.2026.106436.
    PubMed         Abstract available


    J Gen Virol

  10. SASVARI H, Sherry L, Logan N, Dunbar D, et al
    Serological response to feline coronavirus in the UK domestic cat population.
    J Gen Virol. 2026;107:002270.
    PubMed         Abstract available


    J Immunol

  11. SAIDU A, Crawford JC, Walden S, Qu JH, et al
    Highly focused human CD8+ T-cell response in the lower airways during acute influenza infection.
    J Immunol. 2026;215:vkag068.
    PubMed         Abstract available


    J Infect

  12. SMITH CS, Mohmand Z, Hrycyshyn A, Djerboua M, et al
    Risk of severe influenza in people with a history of injection drug use in Ontario: A population-based nested case control study.
    J Infect. 2026 May 20:106764. doi: 10.1016/j.jinf.2026.106764.
    PubMed         Abstract available


    J Virol

  13. BAYUROVA E, Kostyushev D, Tikhonov A, Chulanov V, et al
    Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics.
    J Virol. 2026 Mar 23:e0007726. doi: 10.1128/jvi.00077.
    PubMed         Abstract available

  14. POZHIDAEVA A, Hoch JC, Pustovalova Y
    The DMV pore-forming TM2-Y region of SARS-CoV-2 nsp3 exhibits structural conservation beyond the coronavirus family.
    J Virol. 2026 Apr 3:e0203825. doi: 10.1128/jvi.02038.
    PubMed         Abstract available

  15. RAHEJA H, Sahu R, Ghosh T, Paul S, et al
    HuR enhances SARS-CoV-2 non-structural protein translation through the genomic 5'-UTR, by promoting polypyrimidine tract-binding protein binding.
    J Virol. 2026 Apr 16:e0027626. doi: 10.1128/jvi.00276.
    PubMed         Abstract available

  16. SALISCH F, Muller-Ruttloff C
    Behind the membranous curtain-lipid dynamics and functions in coronaviral replication.
    J Virol. 2026 Apr 21:e0175325. doi: 10.1128/jvi.01753.
    PubMed         Abstract available

  17. GUO D, Yu S, Ma K, Tao H, et al
    Concanavalin A targets phylogenetically conserved N-linked glycans on coronavirus spike proteins for broad-spectrum antiviral activity.
    J Virol. 2026 Apr 27:e0167925. doi: 10.1128/jvi.01679.
    PubMed         Abstract available

  18. NASIR A, Lee D, Avena LE, Berrueta DM, et al
    Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.
    J Virol. 2026 Apr 27:e0022526. doi: 10.1128/jvi.00225.
    PubMed         Abstract available

  19. CHEN L, Su H, Shang W, Nie T, et al
    SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.
    J Virol. 2026 Apr 27:e0222325. doi: 10.1128/jvi.02223.
    PubMed         Abstract available

  20. KOTANI N, Iwasa K, Amimoto T, Yamashita C, et al
    Pseudovirus-mediated proximity labeling identifies candidate host cell membrane proteins involved in viral attachment.
    J Virol. 2026 Apr 29:e0050726. doi: 10.1128/jvi.00507.
    PubMed         Abstract available


    PLoS Comput Biol

  21. KLOCHKOV KA, Kozlov IE, Ilina EN, Manolov AI, et al
    Human mobility and outbreak origins in epidemic spread: Insights from agent-based modeling.
    PLoS Comput Biol. 2026;22:e1014279.
    PubMed         Abstract available


    PLoS One

  22. EL KHATIB Y, Mukhamedova F
    An alternative strategy for balancing profit maximization and risk reduction.
    PLoS One. 2026;21:e0348577.
    PubMed         Abstract available

  23. LINDAHL YL, Noren H, Engstrom AH, Grandahl M, et al
    A solo journey in the shadow of a double-edged pandemic: A qualitative study of women's experience of being pregnant during the COVID-19 pandemic.
    PLoS One. 2026;21:e0349378.
    PubMed         Abstract available

  24. RAUT B, Palla G, Wang J, Campbell S, et al
    ThermiQuant AquaStream: A portable instrument for quantitative colorimetric isothermal nucleic acid amplification reactions in paper and tube formats.
    PLoS One. 2026;21:e0348607.
    PubMed         Abstract available

  25. VISKUPIC F, Daly R, Wiltse DL, Gonda M, et al
    The relationship between personal COVID-19 vaccination decisions and cattle vaccination practices: Evidence from a survey of South Dakota beef producers.
    PLoS One. 2026;21:e0349234.
    PubMed         Abstract available

  26. LENARZ AM, Park H, Roberts MT, Pan A, et al
    The impact of COVID-19 on longevity trends and disparities among Native Americans and Whites in the Four Corners States.
    PLoS One. 2026;21:e0347924.
    PubMed         Abstract available

  27. WILLIAMS H, Armstrong M, Alexander R, Groner J, et al
    Dual pandemic of firearm injury and COVID-19 in Central and Southeastern Ohio: An interrupted time series analysis.
    PLoS One. 2026;21:e0335813.
    PubMed         Abstract available

  28. GONGORA-BENDEZU JA, Martinez-Lopez MV, Aguinaga-Fernandez AD, Yovera-Aldana M, et al
    Post-COVID spirometric abnormalities in workers with intermittent high-altitude exposure: A cross-sectional study in Peru.
    PLoS One. 2026;21:e0329054.
    PubMed         Abstract available

  29. RIOS MONTOYA V, Suarez Alarcon AY, Perez Castillo S, Zamudio Raez T, et al
    Beyond coverage: Can vaccination reduce child mortality despite structural inequality? A global ecological analysis of routine childhood immunization (2010-2023).
    PLoS One. 2026;21:e0340756.
    PubMed         Abstract available

  30. KOO H, Morrow CD
    Shared autonomous HERV loci transcription identifies a unique circulating CD14+-xCR1+ mononuclear cell phenotype in a patient group with post-acute sequelae of COVID-19.
    PLoS One. 2026;21:e0349350.
    PubMed         Abstract available

  31. SHOJI M, Nakaoka K, Ishikawa M, Kasai Y, et al
    Correction: Triethylamine inhibits influenza A virus infection and growth via mechanisms independent of viral neuraminidase and RNA-dependent RNA polymerase.
    PLoS One. 2026;21:e0349522.
    PubMed         Abstract available

  32. LIN J, Chen J, Wan L, He W, et al
    Computational models for the classification of antibody specificity using heavy chain features.
    PLoS One. 2026;21:e0349143.
    PubMed         Abstract available

  33. DENG Y, Tang Z, Chen Q, Hu X, et al
    Computational biology exposed a common pathogenic mechanism in influenza A and Guillain-Barre syndrome.
    PLoS One. 2026;21:e0349687.
    PubMed         Abstract available

  34. ARINAITWE J, Bakamutumaho B, Mugenyi L, Kiwanuka N, et al
    The epidemiology of SARS-CoV-2, Influenza, and Respiratory Syncytial Virus circulation among adult patients with acute respiratory illness in Kampala Metropolitan Area in Uganda.
    PLoS One. 2026;21:e0344869.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A


  35. Correction for Corell-Escuin et al., Dermcidin has antiviral activity and protects against influenza.
    Proc Natl Acad Sci U S A. 2026;123:e2613956123.
    PubMed        

  36. OZA AN, O'Brien KM, Gleeson JP
    Detecting changepoints in dynamical systems: Modeling time-varying transmission of seasonal influenza.
    Proc Natl Acad Sci U S A. 2026;123:e2533861123.
    PubMed         Abstract available


    Vaccine

  37. TANG YS, Chen C, Lv H, Sun Y, et al
    Robust cross-neutralizing antibody responses but variable cellular immunity following either Comirnaty and Spikevax JN.1-adapted mRNA vaccination in the elderly.
    Vaccine. 2026;83:128634.
    PubMed         Abstract available

  38. UKAH UV, Haapala JL, Benitez GV, DeSilva MB, et al
    Language and racial disparities in COVID-19 vaccination during pregnancy and lactation.
    Vaccine. 2026;83:128638.
    PubMed         Abstract available

  39. PAUL KK, Torres M, Shih STF, Gray RT, et al
    Respiratory syncytial virus (RSV) vaccination program for older Australians reduces health inequalities: a distributional cost-effectiveness analysis.
    Vaccine. 2026;83:128644.
    PubMed         Abstract available

  40. TUITE AR, Forbes N, Salvadori MI, Tunis M, et al
    Cost-effectiveness of ongoing COVID-19 vaccination in the context of high population immunity: A structured review of international economic evidence.
    Vaccine. 2026;83:128660.
    PubMed         Abstract available

  41. HARMA V, Palsola M, Kuusipalo A, Lindh E, et al
    Lessons from the 2024 avian influenza vaccination campaign in Finland: a qualitative inquiry.
    Vaccine. 2026;86:128736.
    PubMed         Abstract available

  42. RANQUE B, Galtier F, Nunes H, Le Jeunne C, et al
    Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.
    Vaccine. 2026;86:128732.
    PubMed         Abstract available

Friday, May 22, 2026

Molecular Characterization of #H5N1 Clade 2.3.4.4B Virus in Vaccinated Layer #Chickens

 


Abstract

The global emergence of the avian influenza virus (AIV) H5N1 clade 2.3.4.4B since 2016 has caused substantial losses in wild bird and poultry populations, along with heightened risks of transmission to humans and other mammals. Vaccination of poultry has been a key strategy to curb the virus’s spread and mitigate its socioeconomic impact. This report describes an outbreak of high pathogenicity avian influenza virus (HPAIV) H5N1 clade 2.3.4.4B in a flock of 15,000 brown layer chickens (170 days old), all of which had received a four-dose vaccination regimen with H5N1/H5N8 commercial vaccines at 17, 50, 100, and 125 days of age. Despite this vaccination history, H5N1 infection was confirmed approximately seven weeks post-vaccination. H5N1 infection was confirmed by RT-qPCR, virus isolation, and full genome sequencing covering all eight gene segments, followed by phylogenetic and molecular analyses. Clinical signs included reduced feed intake, decreased egg production, and a cumulative mortality rate of 35% over 52 days. Hemagglutination inhibition (HI) testing with various H5 antigens revealed inconsistent antibody titers (geometric mean: 4.0 to 9.1 log2). Genetic analysis of the full-length HA and NA gene sequences further revealed strong similarity to contemporaneous H5N1 clade 2.3.4.4B strains circulating in Egypt, with multiple mutations in the HA head domain, particularly near immunogenic epitopes and receptor binding sites. These findings highlight the limitations of current vaccination strategies under conditions of antigenic mismatch and complex immunization schedules, emphasizing the need for improved vaccine matching and continuous molecular surveillance. To improve outbreak management in poultry, enhanced vaccination protocols, stringent biosecurity measures, and rigorous monitoring practices are critical.

Source: 


Link: https://www.mdpi.com/1999-4915/18/6/589

____

Epidemiological #surveillance against the #Andes virus: have we learned anything after #COVID19?

 


Summary

Recent outbreaks associated with Andes hantavirus have reignited the international debate on healthcare preparedness for hantaviruses with documented human-to-human transmission. Unlike other orthohantaviruses, Andes hantavirus has demonstrated human-to-human transmission in certain epidemiological contexts, including household and hospital settings. The recent emergence of cases linked to multinational outbreaks has prompted new assessments and recommendations from international public health organizations.

This manuscript presents an epidemiological reflection on the current challenges of surveillance against emerging hantaviruses, drawing on the experience gained during the COVID-19 pandemic. It also reviews aspects related to zoonotic surveillance, molecular monitoring, early detection, and integrated One Health approaches applied to preparedness for future emerging threats.

The available evidence suggests the need to strengthen surveillance systems capable of integrating human, environmental, and animal information to improve the response to complex epidemiological scenarios associated with emerging hantaviruses.

Source: 


Link: https://ojs.sanidad.gob.es/index.php/resp/article/view/1824

____

Updated #trends in #global #prevalence and burden of #mental #disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

 


Summary

Background

The 2023 iteration of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) estimated prevalence, incidence, and health burden for 375 diseases and injuries, including 12 mental disorders. We assess past, current, and emerging trends in the prevalence and burden of mental disorders across sexes and age groups, for 21 regions, 204 countries and territories, and by Socio-demographic Index (SDI) quintile, from 1990 to 2023.

Methods

Mental disorders included in GBD 2023 were anxiety disorders, major depressive disorder, dysthymia, bipolar disorder, schizophrenia, autism spectrum disorders, conduct disorder, attention-deficit hyperactivity disorder, anorexia nervosa, bulimia nervosa, idiopathic developmental intellectual disability, and a residual category of other mental disorders. A literature review identified epidemiological data for each disorder. These were analysed via a Bayesian meta-regression to estimate prevalence by disorder, sex, age, location, and year. Disorder-specific prevalence was multiplied by disability weights representing the severity of health loss associated with each disorder to estimate years lived with disability (YLDs). Deaths due to anorexia nervosa were assessed with a Cause of Death Ensemble modelling strategy to estimate deaths by sex, age, location, and year, and then multiplied by the standard life expectancy at age of death to estimate years of life lost (YLLs). YLDs equalled disability-adjusted life-years (DALYs) for all mental disorders except anorexia nervosa (the only mental disorder considered as an underlying cause of death in GBD), for which DALYs represented the sum of YLDs and YLLs. We presented prevalence, deaths, YLDs, YLLs, and DALYs as counts, age-specific rates per 100 000 population, and age-standardised rates per 100 000 population.

Findings

We estimated 1·17 billion (95% uncertainty interval 1·06–1·31) prevalent cases of mental disorders globally in 2023, equivalent to an age-standardised prevalence rate of 14 210·7 cases (12 849·5–15 940·1) per 100 000 population. These estimates represented a 95·5% (75·0–121·2) increase in prevalent cases and 24·2% (11·4–41·4) increase in age-standardised prevalence rate between 1990 and 2023. All mental disorders showed increases in prevalent cases between 1990 and 2023, while notable increases were seen in age-standardised prevalence rates for anxiety disorders, major depressive disorder, dysthymia, anorexia nervosa, bulimia nervosa, schizophrenia, and conduct disorder. There were an estimated 171 million (127–228) DALYs due to mental disorders globally across sex and age in 2023, equivalent to an age-standardised DALY rate of 2070·5 DALYs (1519·1–2750·5) per 100 000 population. Mental disorders contributed to 6·1% (4·8–7·6) of all-cause DALYs in 2023, making them the fifth leading cause of global DALYs (up from 12th in 1990). DALYs were almost entirely composed of YLDs. Mental disorders were the leading cause of YLDs in 2023 (up from second in 1990), explaining 17·3% (14·8–20·6) of all-cause global YLDs. Leading causes of mental disorder DALYs were anxiety disorders (ranked 11th among the 304 diseases and injuries at Level 4 of the GBD cause hierarchy), major depressive disorder (15th), and schizophrenia (41st). Globally in 2023, mental disorder age-standardised DALY rates were higher among females (2239·6 [1643·7–3014·1] per 100 000) than among males (1900·2 [1399·8–2510·8] per 100 000), and peaked in the 15–19 years age group (2617·3 [1850·6–3696·8] per 100 000). All locations showed increased mental disorder DALY rates in 2023 compared with 1990, ranging across countries and territories from 1302·4 (952·7–1683·7) per 100 000 in Viet Nam to 3555·8 (2661·9–4715·0) per 100 000 in the Netherlands. Across SDI quintiles, DALY rates ranged from 1853·0 (1352·1–2469·3) per 100 000 for middle SDI to 2184·1 (1606·1–2890·3) per 100 000 for high SDI.

Interpretation

A significant health burden was imposed by mental disorders in all countries and territories in 2023, irrespective of the health resources available. In some instances, this burden has increased over time and is unevenly distributed across populations. Stronger surveillance systems, particularly in low-income and middle-income countries, are required. Additionally, we need more coordinated and inclusive policies to reduce the burden through early treatment and prevention, tailored to sex and age differences across locations. Responding to the mental health needs of our global population, especially those most vulnerable, is an obligation, not a choice.

Funding

Gates Foundation, Queensland Health, and University of Queensland.

Source: 


Link: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00519-2/abstract?rss=yes

____

Thursday, May 21, 2026

#Coronavirus #diversity and #SARS-CoV-2 #exposure at the #wildlife – #human interface in Northern #Italy

 


Abstract

Background

Members of the Coronaviridae family infect humans as well as domestic and wild animals. Over the past three decades, three members of this family, all with zoonotic origins, have caused significant epidemics or pandemics (SARS, MERS, and COVID-19). Despite the spread of SARS-CoV-2 being primarily driven by human-to-human transmission, various animal species are susceptible to infection and may contribute to viral circulation. Aim of this work was to monitor coronavirus (CoV) infections in wild mammals in the Emilia-Romagna region (RER), Italy, using a combined approach of molecular screening for viral RNA detection and serological testing for anti-SARS-CoV-2 antibodies.


Methods

Respiratory and gastrointestinal tissue samples were collected from wild animal carcasses between 2022 and 2024. Samples were tested for SARS-CoV-2 using two RT-qPCR assays targeting the E and N genes, and for other CoVs using a nested pan-coronavirus RT-PCR followed by Sanger sequencing of positive samples. Additionally, serum samples obtained from blood, cardiac clot, or thoracic exudate were screened for antibodies against the SARS-CoV-2 nucleocapsid (N) protein, with positive samples subsequently confirmed by an ELISA targeting antibodies to the receptor-binding domain (RBD) of the Spike (S) protein, focused on variants circulating during the study period.


Results

Molecular analyses were performed on 2,238 animals, all of which tested negative for SARS-CoV-2, while 90 (79% hedgehogs) tested positive for CoVs. Among these, most sequences were consistent with coronaviruses typically reported in the respective host species. However, some exceptions – such as Betacoronavirus erinacei in fox, porcupine, hare, and roe deer, and EmbeCoV-related sequences in a porcupine – warrant further attention. Suitable serum samples were available from 1,751 animals. Overall, 65 animals tested positive for anti-N antibodies, 31 of which (22 foxes, 4 badgers, 2 hedgehogs, 1 roe deer, 1 wolf, 1 rat) were subsequently confirmed by an anti-RBD ELISA.


Conclusions

This study provides an overview of CoVs circulation among wild mammals in RER, supporting the role of hedgehogs as reservoirs and identifying some species with evidence of exposure to SARS-CoV-2. Certain unexpected findings highlight the need for further investigations to clarify the potential for cross-species transmission.

Source: 


Link: https://link.springer.com/article/10.1186/s12985-026-03193-3

____

#Andes #Hantavirus #Outbreak on a Cruise #Ship, 2026 (NEJM, summary)

 


Published May 20, 2026 | DOI: 10.1056/NEJMc2606496 | Copyright © 2026


To the Editor:

    On April 27, 2026, a man (later classified as Patient 3 in the outbreak) was medically evacuated to Ascension Island from the Dutch-flagged expedition cruise ship MV Hondius; he had severe acute respiratory infection (SARI) and reported shortness of breath and fever that had begun on April 21. He had signs of pneumonia, although findings on chest radiography were unremarkable. While he was on Ascension Island, his condition worsened, and he was transferred to Johannesburg, South Africa, for ventilator support and intensive care.1 He was in shock and had acute respiratory distress syndrome; findings on chest radiography were consistent with atypical pneumonia. The differential diagnosis in this clinical context is very broad and includes atypical pneumonias, bacterial or fungal sepsis, and vectorborne diseases such as malaria or dengue. The diagnostic evaluation, including respiratory pathogen panels, malaria smear and antigen, fungal biomarkers, blood cultures, and legionella urinary antigen, was unrevealing. Further details are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.

(...)

Source: 


Link: https://www.nejm.org/doi/full/10.1056/NEJMc2606496?query=TOC#ap1

____

Wednesday, May 20, 2026

A mouse #model of #human-derived #H10N3 #influenza enables preclinical evaluation of #antiviral efficacy

 


Highlights

• Revealing one human-derived H10N3 virus was highly lethal to C57BL/6J, ICR, and BALB/c mice;

• Successfully establishing the first human-derived H10N3-infected mice model.

• In vitro antiviral assay revealed that this human-origin H10N3 virus exhibits natural resistance to oseltamivir, but remains sensitive to peramivir and baloxavir.

• Oseltamivir or BM immediate treatment after infection effectively prevented mortality caused by H10N3,but their efficacy with a 24h delay were significantly weaker than that of peramivir.

• BM one-dose treatment with a 24h delay has no protective effect, but BM combination with NAIs exhibits significant additive effect on mortality caused by H10N3.

• BM and NAIs combination may be a promising therapy for combating novel H10N3 virus infection.


Abstract

    Human infections with avian influenza A (H10N3) have recently been reported, representing a notable global public health concern. To seek effective strategies for emerging H10N3 virus infection and provide tools for vaccine and antiviral drugs development, we established a mouse model with a novel human-derived H10N3 virus. Our findings revealed that this human-derived H10N3 virus was highly lethal to C57BL/6J, ICR, and BALB/c mice. Neuraminidase inhibitors (oseltamivir or peramivir) effectively conferred protection for H10N3 low-lethal infection, but the efficacy of peramivir is superior to that of oseltamivir. One single dose of baloxavir marboxil (BM) treatment at 2 h post-infection provides complete protection against mortality, but BM treatment with a 24h delay has no protective effect against mortality caused by H10N3 virus infection. Furthermore, BM multiple doses treatment with a 24h delay for H10N3 infection remains effective in preventing weight loss and enhancing viral clearance, but its protective efficacy against mortality was significantly attenuated. However, both in vitro and in vivo combination of BM with NAIs exhibit significant additive effect against H10N3 virus infection than BM or NAIs monotherapy. Our findings suggest that combination of BM with NAIs represents a promising therapeutic strategy for emerging H10N3 infections in clinical practice.

Source: 


Link: https://www.sciencedirect.com/science/article/abs/pii/S0166354226000951?via%3Dihub

____

Saturday, May 16, 2026

Imported case of avian #influenza #H9N2 virus #infection in a patient with miliary #tuberculosis, #Italy, March 2026

 


Abstract

On 21 March 2026, avian influenza A(H9N2) virus was confirmed in Italy in a patient with miliary tuberculosis. The patient had recently travelled to West Africa. Following the detection of an unsubtypable influenza A virus, rapid molecular confirmation and full genome sequencing were performed. Phylogenetic analysis revealed that the virus belonged to subclade G5.5 and was closely related to African strains. Epidemiological investigations identified no additional cases, suggesting there was no evidence of onward transmission at the time of reporting.

Source: 


Link: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.15.2600285#abstract_content

____

#Coronavirus Disease Research #References (AMEDEO, May 16 '26)

 


    Ann Intern Med

  1. JOHNSON D, Quinn S, Algase LF, Watkins C Jr, et al
    Telemedicine Policy and Practice: A Position Paper From the American College of Physicians.
    Ann Intern Med. 2026 May 12. doi: 10.7326/ANNALS-25-04194.
    PubMed         Abstract available


    BMJ

  2. SUMMERS C, Cook T, Suntharalingam G, Fong K, et al
    Covid Inquiry module 3 reveals critical gaps in UK health system resilience.
    BMJ. 2026;393:s846.
    PubMed        


    Br J Anaesth

  3. FRASER S, Syratt T, Bridson JD, Gilbert-Kawai N, et al
    Refusal of blood transfusion based on donor COVID-19 vaccination status: an emerging postpandemic challenge for perioperative care.
    Br J Anaesth. 2026 May 13:S0007-0912(26)00279-5. doi: 10.1016/j.bja.2026.
    PubMed        


    Clin Infect Dis

  4. PEREZ MA, Patel KA, Rasmy L, Yoshida H, et al
    Changes in Epidemiology of Candidemia in the United States with a Focus on Candida auris.
    Clin Infect Dis. 2026 May 11:ciag312. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  5. MENG L, Bell JM, Barbre K, Guthrie S, et al
    Using a longitudinal k-means clustering method to explore nursing home factors associated with SARS-CoV-2 infection peak and resilience to a COVID-19 surge.
    Infect Control Hosp Epidemiol. 2026 May 14:1-7. doi: 10.1017/ice.2026.10406.
    PubMed         Abstract available


    Int J Infect Dis

  6. KIM S, Chun BC
    Heterogeneous Rebound Patterns of Foodborne Diseases after COVID-19 Non-Pharmaceutical Interventions, South Korea, 2005-2024.
    Int J Infect Dis. 2026 May 13:108782. doi: 10.1016/j.ijid.2026.108782.
    PubMed         Abstract available

  7. WENG TP, Li MC, Tsai HP, Chen CJ, et al
    Viral Rebound and Clinical Outcomes in Hospitalized Patients with COVID-19.
    Int J Infect Dis. 2026 May 13:108796. doi: 10.1016/j.ijid.2026.108796.
    PubMed         Abstract available

  8. SHI R, Li Y, Liu L, Wang Y, et al
    Molecular epidemiology and genomic characterization of post-pandemic macrolide-resistant Mycoplasma pneumoniae in hospitalized children.
    Int J Infect Dis. 2026 May 13:108780. doi: 10.1016/j.ijid.2026.108780.
    PubMed         Abstract available

  9. MARTINEZ-DIAZ I, Nunez-Delgado S, Ortiz-Perez JT, Morales A, et al
    Increased circulating ACE2 and GAS6 are independent predictors of COVID-19 severity.
    Int J Infect Dis. 2026 May 12:108775. doi: 10.1016/j.ijid.2026.108775.
    PubMed         Abstract available

  10. HEYMER EJ, Campbell H, Clark SA, Lucidarme J, et al
    Lower incidence and higher case fatality rates associated with invasive meningococcal disease during COVID-19 pandemic restrictions (March 2020 to July 2021) in England.
    Int J Infect Dis. 2026 May 10:108770. doi: 10.1016/j.ijid.2026.108770.
    PubMed         Abstract available

  11. NIAMSANIT S, Sitthikarnkha P, Techasatian L, Saengnipanthkul S, et al
    Incidence Trends, Outcomes, and Factors Associated with Mortality in Multisystem Inflammatory Syndrome in Children: A Nationwide Study in Thailand during 2021-2023.
    Int J Infect Dis. 2026 May 6:108766. doi: 10.1016/j.ijid.2026.108766.
    PubMed         Abstract available


    J Med Virol

  12. YAVUZ HC, Boysan SN, Tuna MM
    FIB-4 Index and APRI Score Predict Short- and Long-Term Mortality in Hospitalized COVID-19 Patients: A 4-Year Follow-Up Study.
    J Med Virol. 2026;98:e70964.
    PubMed         Abstract available

  13. KIM DS, Kim U, Woo HM, Lee H, et al
    Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2.
    J Med Virol. 2026;98:e70969.
    PubMed         Abstract available


    J Virol

  14. MCCABE M, Groves HE, Getty E, Campbell E, et al
    Age-dependent expression and antiviral activity of interferon epsilon in respiratory epithelium.
    J Virol. 2026 May 12:e0057825. doi: 10.1128/jvi.00578.
    PubMed         Abstract available

  15. LI P, Zheng Y-M, Liu S-L
    Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.
    J Virol. 2026 May 12:e0001626. doi: 10.1128/jvi.00016.
    PubMed         Abstract available


    Lancet Infect Dis

  16. HANSEN CH, Soborg B, Rasmussen M, Moustsen-Helms IR, et al
    Effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalisation and death: a Danish nationwide cohort study.
    Lancet Infect Dis. 2026 May 13:S1473-3099(26)00236.
    PubMed        


    N Engl J Med

  17. HAYDEN FG, Shinkai M, Clark TW, Luetkemeyer AF, et al
    Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
    N Engl J Med. 2026;394:1905-1915.
    PubMed         Abstract available


    Nature

  18. DOLGIN E
    At last, a pill that can prevent COVID after exposure to infected people.
    Nature. 2026 May 13. doi: 10.1038/d41586-026-01546.
    PubMed        


    Science

  19. LESSLER J, Christensen A
    From wastewater analysis to public health action.
    Science. 2026;392:692.
    PubMed         Abstract available

  20. HILL DT, Schulman R, Caldas IV, Dunham C, et al
    Genetic variability of SARS-CoV-2 in wastewater and associations with community transmission.
    Science. 2026;392:735-741.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 16 '26)

 


    Antiviral Res

  1. PANG L, Zou J, Yuan Z, Zhao P, et al
    Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity.
    Antiviral Res. 2026;250:106417.
    PubMed         Abstract available


    Cell

  2. QIAN W, Wei X, Barros AJ, Ye X, et al
    Respiratory viral infections prime accelerated lung cancer growth.
    Cell. 2026;189:2845-2856.
    PubMed         Abstract available


    Drug Saf

  3. SHETTY AN, Mallard JH, Hennessy D, Wood N, et al
    Giant Cell Arteritis Following COVID-19 Vaccination: A Consumer-Stimulated Analysis.
    Drug Saf. 2026;49:705-715.
    PubMed         Abstract available


    J Clin Microbiol

  4. SMITH ZR, Godoshian A, Boersma P, Myrick C, et al
    Evaluation of self-collection of nasal swab specimens for COVID-19 diagnostic testing in children in the United States, 2020-2023.
    J Clin Microbiol. 2026;64:e0133625.
    PubMed         Abstract available


    J Gen Virol

  5. BHAT S, Sadeyen JR, Yang J, Chrzastek K, et al
    A G57 (BJ/94-like) H9N2 avian influenza virus exhibits enhanced replication and tissue dissemination in chickens compared with a G1-B virus.
    J Gen Virol. 2026;107.
    PubMed         Abstract available


    J Infect Dis

  6. COLDBECK-SHACKLEY RC, Flynn E, Mudhar AK, Taouk ML, et al
    Increased Diversity and Introduction of Multidrug-Resistant Strains of Neisseria gonorrhoeae Following Cessation of COVID-19 Pandemic-Related Travel Restrictions: An Observational Genomic Epidemiologic Study.
    J Infect Dis. 2026;233:e1130-e1140.
    PubMed         Abstract available

  7. LUCENA LAGE S, Rocco JM, Oguz C, Otaizo-Carrasquero F, et al
    Inflammasome Activation and Oxidative Stress in SARS-CoV-2 Infection and Symptomatic Rebound.
    J Infect Dis. 2026;233:e1285-e1297.
    PubMed         Abstract available

  8. BOECKH M, Xie H, Stevens-Ayers T, Sircy L, et al
    Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.
    J Infect Dis. 2025 Dec 31:jiaf649. doi: 10.1093.
    PubMed         Abstract available

  9. ZHANG R, Shang X, Wang C, Zhou H, et al
    Rhinovirus-Associated Lower Respiratory Tract Infection in Hospitalized Adult Patients: A Retrospective Cohort Study.
    J Infect Dis. 2026;233:868-876.
    PubMed         Abstract available


    J Virol

  10. XU C, Peng Y, Liu S, Xie R, et al
    Cellular hnRNP D promotes influenza A virus replication by inhibiting TBK1-IRF3-mediated innate immune response.
    J Virol. 2026 May 13:e0025726. doi: 10.1128/jvi.00257.
    PubMed         Abstract available

  11. CHEN X, Zheng X, Zhang L, Cai X, et al
    Long noncoding RNA#61 synergizes with viral PA-X to augment pyroptosis and attenuate the virulence of highly pathogenic H5N1 influenza virus in mice.
    J Virol. 2026 May 12:e0221425. doi: 10.1128/jvi.02214.
    PubMed         Abstract available

  12. VAN PUL L, Rosendahl Huber SK, Jacobi R, Hendriks M, et al
    Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.
    J Virol. 2026 May 12:e0040726. doi: 10.1128/jvi.00407.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  13. ROLFES MA, Bauck L, Lipton BA, Margrey SF, et al
    Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks - United States, July-December 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:234-239.
    PubMed         Abstract available

  14. ROLFES MA, Bauck L, Lipton BA, Margrey SF, et al
    Knowledge, Attitudes, and Practices Regarding Avian Influenza Among Owners of Backyard Flocks - United States, July-December 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:234-239.
    PubMed         Abstract available


    N Engl J Med

  15. HAYDEN FG, Shinkai M, Clark TW, Luetkemeyer AF, et al
    Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts.
    N Engl J Med. 2026;394:1905-1915.
    PubMed         Abstract available


    PLoS Comput Biol

  16. KIERAN TJ, Maines TR, Belser JA
    Limited 'heft' of weight-based outcomes in predicting influenza A virus disease severity in ferrets.
    PLoS Comput Biol. 2026;22:e1014210.
    PubMed         Abstract available

  17. YU G, Garee M, Ventresca M, Yih Y, et al
    Modeling individual self-protective behavior during epidemics.
    PLoS Comput Biol. 2026;22:e1014252.
    PubMed         Abstract available


    PLoS Med

  18. GOODFELLOW L, Quilty BJ, van Zandvoort K, Edmunds WJ, et al
    Social contact patterns in the United Kingdom following the COVID-19 pandemic: The Reconnect cross-sectional survey.
    PLoS Med. 2026;23:e1005038.
    PubMed         Abstract available


    PLoS One

  19. ZOUGHEIB Y, Salameh N, Slim A, Wehbi Z, et al
    Effect of screen time and outdoor activities on myopia progression.
    PLoS One. 2026;21:e0347118.
    PubMed         Abstract available

  20. YEHIA N, Ibrahim M, Shady RM, Mohamed AAE, et al
    Concurrent circulation of avian influenza viruses H5N1 and H9N2 enhances the genetic evolution of reassortant viruses in Egyptian poultry populations.
    PLoS One. 2026;21:e0348609.
    PubMed         Abstract available

  21. CANTON L, Schalkwijk P, Landier J, Rebaudet S, et al
    Socioeconomic inequalities and the COVID-19 pandemic in France: Territorial analyzes based on epidemic wave and metropolitan area.
    PLoS One. 2026;21:e0348201.
    PubMed         Abstract available

  22. SUGIYAMA A, Takafuta T, Abe K, Yoshinaga Y, et al
    Differences in the long-term course of post-COVID-19 symptoms in adults and children across epidemic periods: A retrospective cohort study in Japan, 2020-2024.
    PLoS One. 2026;21:e0348954.
    PubMed         Abstract available

  23. HUGHES A, Barnard S, Bauer-Staeb C, Holleyman R, et al
    Life lost due to the COVID-19 pandemic: A model-based cohort analysis of mortality displacement in the registered population of England.
    PLoS One. 2026;21:e0348575.
    PubMed         Abstract available

  24. LIU Y, Lu E, Ellingson KD, Hollister J, et al
    Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naive individuals associated with Omicron breakthrough infections.
    PLoS One. 2026;21:e0347602.
    PubMed         Abstract available

  25. FREITAS EL, Erbisti RS, Grinberg-Weller B, Pinto DCC, et al
    Spatiotemporal analysis of psychoactive drug consumption in Brazil during the COVID-19 pandemic.
    PLoS One. 2026;21:e0343552.
    PubMed         Abstract available

  26. TOGEL J, Kuhbandner C
    Fear and the internalization of external regulation - An exploratory study on how fear of COVID-19 affected the internalization of mask-wearing.
    PLoS One. 2026;21:e0347772.
    PubMed         Abstract available

  27. MILLER SL, Yan S, Garcia A, Wang LL, et al
    Potential airborne transmission of SARS-COV-2 through bathroom ventilation ducts associated with an outbreak in a residential building in Santander, Spain, 2020.
    PLoS One. 2026;21:e0345041.
    PubMed         Abstract available

  28. DOMINGUEZ-MONTERROZA A, Jimenez-Martin A, Mateos Caballero A
    Network geometry, topology, and spectral analysis in global stock markets: Insights from using the Ricci curvature, Euler characteristic, and random matrix theory.
    PLoS One. 2026;21:e0347767.
    PubMed         Abstract available

  29. BRAUN J, Kopp J, Kunzi L, Puhan MA, et al
    Measurement properties of the 30-second sit-to-stand test in post COVID-19 condition: Results from the PYCNOVID randomised controlled trial.
    PLoS One. 2026;21:e0348275.
    PubMed         Abstract available

  30. LAURENCE J, Smyth E
    COVID-19 pandemic stressors and their longer-term association with young people's wellbeing.
    PLoS One. 2026;21:e0347875.
    PubMed         Abstract available

  31. SCHERBOV S, Pothisiri W, Prasitsiriphon O, Ediev DM, et al
    Survival and life expectancy inequality by gender in Thai provinces: Trends from 2015 to 2023.
    PLoS One. 2026;21:e0348587.
    PubMed         Abstract available

  32. AZANERO-HARO J, Soto A
    Comparison of the performance of four clinical prediction rules for mortality in patients with COVID-19.
    PLoS One. 2026;21:e0348683.
    PubMed         Abstract available

  33. PENG Y
    Sustainability-induced loyalty in festival tourism: Examining the mediating pathways between sustainable practices and visitor behavioral support.
    PLoS One. 2026;21:e0348506.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  34. KEARNS FL, Bogetti AT, Calvo-Tusell C, Braza MKE, et al
    D614G reshapes allosteric networks and opening mechanisms of SARS-CoV-2 spikes.
    Proc Natl Acad Sci U S A. 2026;123:e2504793123.
    PubMed         Abstract available

  35. SIMKO T, Johnson RA
    Alleviating administrative burdens in rental assistance promotes access and program efficiency.
    Proc Natl Acad Sci U S A. 2026;123:e2512756123.
    PubMed         Abstract available


    Vaccine

  36. CARLOCK MA, Ross TM
    Retooling a novel influenza B hemagglutinin to redirect neutralizing antibodies against B/Victoria strains.
    Vaccine. 2026;84:128674.
    PubMed         Abstract available


    Virology

  37. WANG R, Chen J, Zhang H, Qin Y, et al
    Characterization of monoclonal antibody and identification of two novel linear epitopes on the hemagglutinin protein of H3N2 canine influenza virus.
    Virology. 2026;621:110923.
    PubMed         Abstract available

  38. DING K, Ding Y
    H5N1 avian influenza in dairy cattle: Molecular adaptation, transmission mechanisms, and control strategies.
    Virology. 2026;621:110927.
    PubMed         Abstract available

  39. ZHANG Y, Liu L, Chen T, Li M, et al
    CD25(+) cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice.
    Virology. 2026;621:110938.
    PubMed         Abstract available

Membrane-anchored #influenza #neuraminidase vaccine drives #human-like broadly protective B cell responses

 



Abstract

Influenza neuraminidase (NA) is a promising target for universal flu vaccines, yet eliciting potent B-cell responses against its conserved epitopes remains challenging. Here, we developed a membrane-anchored, folding-domain-free NA (mNA) that elicited superior head-specific germinal center B cell and antibody responses compared to soluble tetrameric NA. In non-human primates, mNA immunization induced cross-reactive memory B cell (MBC) responses, expanding clones with the conserved DR motif in HCDR3, a hallmark of human broadly reactive NA antibodies. These MBCs conferred cross-inhibitory activity against diverse NA variants and in vivo cross-protection. Cryo-EM analysis revealed that the 554-C2 clone targets the conserved enzymatic pocket via the DR motif, while the 554-C1 clone recognizes previously uncharacterized epitopes at the interface between two adjacent N2 monomers, effectively reducing plaque formation by contemporary H3N2 strains. Our findings highlight the immunological advantages of membrane-anchoring, providing a robust strategy for designing next-generation vaccines against influenza and other pathogens.


Competing Interest Statement

Westlake University has filed for patent protection for mNA used as an influenza vaccine.


Funder Information Declared

State Key Laboratory of Gene Expression, SKLGE-ZX-2025007

Zhejiang Provincial Key Laboratory Construction Project, 2024ZY01026, 2024E10060, 2024E10052

Natural Science Foundation of Zhejiang province, LR26H190001

National Natural Science Foundation of China, 82471855, 825B2062, 82330054, 82502209, 32471303

Source: 


Link: https://www.biorxiv.org/content/10.64898/2026.05.13.724804v1

____

My New Space

Most Popular Posts